STOCK TITAN
  1. Home
  2. News
  3. MPSYF

MORPHOSYS AG ORD - $MPSYF STOCK NEWS

Welcome to our dedicated page for MORPHOSYS ORD news (Ticker: $MPSYF), a resource for investors and traders seeking the latest updates and insights on MORPHOSYS ORD stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MORPHOSYS ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MORPHOSYS ORD's position in the market.

News
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Rhea-AI Summary
MorphoSys AG will present new Phase 3 MANIFEST-2 data on pelabresib in myelofibrosis at the 2024 ASCO Annual Meeting. The presentation will include efficacy and safety data from the trial of pelabresib in combination with ruxolitinib in JAK inhibitor-naïve patients. Additional data from the Phase 2 study of tulmimetostat will also be showcased. The ASCO 2024 congress will be held in Chicago, Illinois, from May 31 to June 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
conferences clinical trial
-
News
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Rhea-AI Summary
MorphoSys AG receives U.S. antitrust clearance for acquisition by Novartis AG, with a proposed takeover offer of € 68.00 per share, totaling € 2.7 billion. The offer document expected in April 2024, with a minimum acceptance threshold of 65% of share capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
acquisition
-
News
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Rhea-AI Summary
MorphoSys AG to release financial year 2023 results on March 13, 2024, with a conference call and webcast scheduled on March 14, 2024. The Management team will present the results and outlook for 2024, followed by a Q&A session. Participants can join via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
News
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
MorphoSys AG (MOR) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.66%
Tags
conferences
-
News
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
Rhea-AI Summary
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will release its Q3 and first nine months 2023 results on November 15, 2023, with a conference call and webcast on November 16, 2023. The Management team will present the results and outlook, followed by a Q&A session. Participants can join via phone or webcast, with a replay available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.06%
Tags
earnings
-
News
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Rhea-AI Summary
MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib will be presented at the ASH Annual Meeting. The trial evaluated the investigational BET inhibitor in combination with the JAK inhibitor ruxolitinib in myelofibrosis patients. The company will also share topline results from the study in the coming weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
clinical trial
News
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Rhea-AI Summary
MorphoSys reports preliminary Q3 2023 net product sales of $23.4 million for Monjuvi in the US. Full year 2023 sales expected to be $85-95 million with a gross margin of approximately 75%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
earnings
-
News
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Rhea-AI Summary
MorphoSys AG's tulmimetostat receives Fast Track designation from FDA for the treatment of endometrial cancer with ARID1A mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
clinical trial
-
News
Invitation to MorphoSys' Full Year Results 2022 Conference Call on March 16, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
News
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
clinical trial
Stock MPSYF logo
MORPHOSYS AG ORD

Nasdaq:MPSYF

MPSYF Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

MPSYF Stock Data

2.74B
33.15M
4.7%
80.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Planegg

About MPSYF

morphosys developed hucal, the most successful antibody library technology in the pharmaceutical industry. by successfully applying this and other patented technologies, morphosys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. together with its pharmaceutical partners, morphosys has built a therapeutic pipeline of more than 100 human antibody drug candidates and other biologics for the treatment of cancer, rheumatoid arthritis, and alzheimer’s disease, to name just a few. with its ongoing commitment to new antibody technology and drug development, morphosys is focused on making the healthcare products of tomorrow. morphosys is listed on the frankfurt stock exchange under the symbol mor.